Bryan M. Reasons Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Bryan M. Reasons.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Bryan M. Reasons. Bryan M. Reasons is Chief Financial Officer in IMPAX LABORATORIES INC ($IPXL) and Director in Aclaris Therapeutics, Inc. ($ACRS) and EVP & CFO in Mallinckrodt plc ($MNK) and Director in Recro Pharma, Inc. ($REPH) and CFO in Amneal Pharmaceuticals, Inc. ($AMRX).
Latest Insider Trading Transactions of Bryan M. Reasons
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AMRX, IPXL, MNK, REPH
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 26,923 | 0 | 67,429 | 40.5 K to 67.4 K (+66.47 %) |
Dec 07 2020 | MNK | Mallinckrodt plc | Reasons Bryan M. | EVP & CFO | Sell | S | 0.17 | 5,400 | 891 | 11,593 | 17 K to 11.6 K (-31.78 %) |
Jun 08 2020 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Option Exercise | M | 0.00 | 7,333 | 0 | 0 | |
Jun 08 2020 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Option Exercise | A | 1.41 | 16,500 | 23,265 | 16,500 | |
Jun 08 2020 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Buy | M | 0.00 | 7,333 | 0 | 16,209 | 8.9 K to 16.2 K (+82.62 %) |
May 11 2020 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 8.37 | 12,405 | 103,830 | 12,405 | |
May 11 2020 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 8,363 | 0 | 40,506 | 32.1 K to 40.5 K (+26.02 %) |
Apr 03 2020 | MNK | Mallinckrodt plc | Reasons Bryan M. | EVP & CFO | Payment of Exercise | F | 1.93 | 986 | 1,903 | 16,993 | 18 K to 17 K (-5.48 %) |
Mar 04 2020 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Option Exercise | M | 0.00 | 8,876 | 0 | 0 | |
Mar 04 2020 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Option Exercise | A | 0.00 | 8,876 | 0 | 8,876 | |
Mar 04 2020 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Buy | M | 0.00 | 8,876 | 0 | 8,876 | 0 to 8.9 K |
Dec 09 2019 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 9,156 | 0 | 32,143 | 23 K to 32.1 K (+39.83 %) |
Jun 10 2019 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Option Exercise | A | 0.00 | 7,333 | 0 | 7,333 | |
Jun 07 2019 | MNK | Mallinckrodt plc | Reasons Bryan M. | EVP & CFO | Buy | P | 8.96 | 5,400 | 48,383 | 17,979 | 12.6 K to 18 K (+42.93 %) |
May 10 2019 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 8.80 | 10,888 | 95,814 | 10,888 | |
May 10 2019 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 7,955 | 0 | 22,987 | 15 K to 23 K (+52.92 %) |
Apr 03 2019 | MNK | Mallinckrodt plc | Reasons Bryan M. | EVP & CFO | Option Exercise | A | 22.26 | 57,569 | 1,281,486 | 57,569 | |
Apr 03 2019 | MNK | Mallinckrodt plc | Reasons Bryan M. | EVP & CFO | Grant | A | 0.00 | 12,579 | 0 | 12,579 | 0 to 12.6 K |
Aug 23 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Sell | S | 23.65 | 11,698 | 276,658 | 82,986 | 94.7 K to 83 K (-12.35 %) |
Aug 23 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Sell | S | 23.65 | 11,698 | 276,658 | 82,986 | 94.7 K to 83 K (-12.35 %) |
May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | M | 0.00 | 8,849 | 0 | 0 | |
May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | M | 0.00 | 8,849 | 0 | 0 | |
May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Buy | M | 0.00 | 8,849 | 0 | 15,032 | 6.2 K to 15 K (+143.12 %) |
May 14 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Buy | M | 0.00 | 8,849 | 0 | 15,032 | 6.2 K to 15 K (+143.12 %) |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Option Exercise | A | 0.00 | 33,311 | 0 | 33,311 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Option Exercise | A | 15.01 | 136,240 | 2,044,962 | 136,240 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Option Exercise | A | 17.99 | 52,000 | 935,480 | 52,000 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Option Exercise | A | 25.24 | 55,000 | 1,388,200 | 55,000 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Option Exercise | A | 40.70 | 47,500 | 1,933,250 | 47,500 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Option Exercise | A | 33.27 | 63,095 | 2,099,171 | 63,095 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Option Exercise | A | 9.35 | 56,232 | 525,769 | 56,232 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | Reasons Bryan M. | CFO | Grant | A | 0.00 | 94,684 | 0 | 94,684 | 0 to 94.7 K |
May 08 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 11.32 | 5,742 | 64,999 | 5,742 | |
May 08 2018 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 6,183 | 0 | 6,183 | 0 to 6.2 K |
May 08 2018 | IPXL | Impax Laboratories ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | D | 17.99 | 52,000 | 935,480 | 0 | |
May 08 2018 | IPXL | Impax Laboratories ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | D | 25.24 | 55,000 | 1,388,200 | 0 | |
May 08 2018 | IPXL | Impax Laboratories ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | D | 40.70 | 47,500 | 1,933,250 | 0 | |
May 08 2018 | IPXL | Impax Laboratories ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | D | 33.27 | 63,095 | 2,099,171 | 0 | |
May 08 2018 | IPXL | Impax Laboratories ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | D | 9.35 | 56,232 | 525,769 | 0 | |
May 08 2018 | IPXL | Impax Laboratories ... | Reasons Bryan M. | Chief Financial Off ... | Sell | D | 0.00 | 20,566 | 0 | 0 | 20.6 K to 0 (-100.00 %) |
May 08 2018 | IPXL | Impax Laboratories ... | Reasons Bryan M. | Chief Financial Off ... | Sell | D | 0.00 | 53,423 | 0 | 0 | 53.4 K to 0 (-100.00 %) |
Apr 23 2018 | ACRS | Aclaris Therapeuti ... | Reasons Bryan M. | Director | Option Exercise | A | 17.73 | 16,000 | 283,680 | 16,000 | |
Mar 05 2018 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 19.50 | 3,069 | 59,846 | 94,684 | 97.8 K to 94.7 K (-3.14 %) |
Feb 27 2018 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 20.95 | 6,141 | 128,654 | 97,753 | 103.9 K to 97.8 K (-5.91 %) |
May 16 2017 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 16.80 | 454 | 7,627 | 103,894 | 104.3 K to 103.9 K (-0.44 %) |
May 16 2017 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 17.65 | 705 | 12,443 | 104,348 | 105.1 K to 104.3 K (-0.67 %) |
Mar 06 2017 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 7.63 | 20,000 | 152,600 | 20,000 | |
Mar 06 2017 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | A | 9.35 | 56,232 | 525,769 | 56,232 | |
Mar 06 2017 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Grant | A | 0.00 | 23,272 | 0 | 105,053 | 81.8 K to 105.1 K (+28.46 %) |
Feb 27 2017 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 14.05 | 5,715 | 80,296 | 81,781 | 87.5 K to 81.8 K (-6.53 %) |
Oct 27 2016 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 21.35 | 1,209 | 25,812 | 87,496 | 88.7 K to 87.5 K (-1.36 %) |
May 16 2016 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 29.18 | 1,216 | 35,483 | 88,705 | 89.9 K to 88.7 K (-1.35 %) |
May 16 2016 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 29.18 | 1,889 | 55,121 | 89,921 | 91.8 K to 89.9 K (-2.06 %) |
Mar 01 2016 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | A | 33.27 | 63,095 | 2,099,171 | 63,095 | |
Mar 01 2016 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Grant | A | 0.00 | 26,113 | 0 | 92,845 | 66.7 K to 92.8 K (+39.13 %) |
Mar 01 2016 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 33.27 | 1,958 | 65,143 | 66,732 | 68.7 K to 66.7 K (-2.85 %) |
Apr 14 2016 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 35.35 | 1,035 | 36,587 | 91,810 | 92.8 K to 91.8 K (-1.11 %) |
Oct 27 2015 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 35.97 | 1,299 | 46,725 | 68,690 | 70 K to 68.7 K (-1.86 %) |
May 19 2015 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 44.44 | 1,391 | 61,816 | 69,989 | 71.4 K to 70 K (-1.95 %) |
May 19 2015 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 44.82 | 2,161 | 96,856 | 71,380 | 73.5 K to 71.4 K (-2.94 %) |
Apr 15 2015 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 50.90 | 1,205 | 61,335 | 73,541 | 74.7 K to 73.5 K (-1.61 %) |
Mar 12 2015 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | A | 40.70 | 47,500 | 1,933,250 | 47,500 | |
Mar 12 2015 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Grant | A | 0.00 | 20,000 | 0 | 74,746 | 54.7 K to 74.7 K (+36.53 %) |
Oct 28 2014 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 27.80 | 940 | 26,132 | 54,746 | 55.7 K to 54.7 K (-1.69 %) |
May 16 2014 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | A | 25.24 | 55,000 | 1,388,200 | 55,000 | |
May 16 2014 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 25.56 | 1,400 | 35,784 | 55,686 | 57.1 K to 55.7 K (-2.45 %) |
May 16 2014 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Grant | A | 0.00 | 23,000 | 0 | 57,086 | 34.1 K to 57.1 K (+67.48 %) |
Apr 14 2014 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 24.55 | 1,216 | 29,853 | 34,086 | 35.3 K to 34.1 K (-3.44 %) |
Oct 28 2013 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 20.47 | 939 | 19,221 | 35,302 | 36.2 K to 35.3 K (-2.59 %) |
May 16 2013 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Option Exercise | A | 17.99 | 52,000 | 935,480 | 52,000 | |
May 16 2013 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Grant | A | 0.00 | 14,800 | 0 | 36,241 | 21.4 K to 36.2 K (+69.03 %) |
Apr 16 2013 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Payment of Exercise | F | 16.46 | 1,159 | 19,077 | 21,441 | 22.6 K to 21.4 K (-5.13 %) |
Feb 15 2013 | IPXL | IMPAX LABORATORIES ... | Reasons Bryan M. | Chief Financial Off ... | Grant | A | 0.00 | 10,000 | 0 | 22,600 | 12.6 K to 22.6 K (+79.37 %) |
Page: 1